ARCHIVES

Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For CML

This article is from The Cancer Letter archive.

Vol. 30 No. 12 | December 28, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: Patent For Semisynthetic Taxol Issued To FL Scientist; Simone To Chair Pediatric Group

June 7, 1991

In a letter, ASCO reaffirms its views on oncology consolidation at FDA.

July 9, 2004

Moddelmog Steps Down At Komen For the Cure

November 20, 2009

ImClone “Screwed Up,” CEO Waksal Tells Conference; Stock Plunges.

January 11, 2002

ASCO Proposes Principles For Future Debate on Medicaid

November 21, 2014

Cancer Genome Atlas Researchers Link Cell Metabolism Pathways To Disease Aggressiveness

July 26, 2013